Prostate Specific Antigen (PSA) Test Market Report 2026
Global Outlook – By Type (Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Types), By Application (Screening, Post-Treatment Monitoring, Other Applications), By End User (Hospitals, Diagnostic Centers, Research Institutes, Other End Users) - Market Size, Trends, Strategies, and Forecast to 2030
Prostate Specific Antigen (PSA) Test Market Overview
• Prostate Specific Antigen (PSA) Test market size has reached to $4.65 billion in 2025 • Expected to grow to $8.17 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Increasing Prevalence Of Prostate Cancer Drives Growth In Prostate-Specific Antigen (PSA) Test Market • Market Trend: Innovations With Home Testing Kits For Prostate-Specific Antigen (PSA) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Prostate Specific Antigen (PSA) Test Market?
The prostate-specific antigen (PSA) test is a blood test that quantifies the presence of prostate-specific antigen in the body. This test is primarily used to screen for and monitor prostate cancer in men and measures the level of prostate-specific antigen in the blood. The main types of prostate-specific antigen (PSA) tests are clinical laboratory improvement amendments (CLIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and others. Clinical laboratory improvement amendments (CLIA) refer to a set of rules that govern laboratory testing and mandate that clinical laboratories obtain CMS certification before accepting human samples for diagnostic testing. These are used for several applications, including screening, post-treatment monitoring, and others, and by various end-users such as hospitals, diagnostic centers, research institutes, and others.
What Is The Prostate Specific Antigen (PSA) Test Market Size and Share 2026?
The prostate specific antigen (psa) test market size has grown rapidly in recent years. It will grow from $4.65 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing use of psa testing in clinical practice, expansion of laboratory diagnostic services, rising awareness of prostate cancer screening, availability of immunoassay-based test kits, integration of psa testing into routine checkups.What Is The Prostate Specific Antigen (PSA) Test Market Growth Forecast?
The prostate specific antigen (psa) test market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to advancement of high-precision psa assay technologies, growing adoption of decentralized diagnostic testing, expansion of preventive cancer screening initiatives, increasing investments in diagnostic automation, rising demand for cost-effective screening solutions. Major trends in the forecast period include increasing adoption of routine psa screening programs, rising demand for point-of-care psa testing, growing use of high-sensitivity immunoassays, expansion of post-treatment monitoring applications, enhanced focus on early cancer detection.
Global Prostate Specific Antigen (PSA) Test Market Segmentation
1) By Type: Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Types 2) By Application: Screening, Post-Treatment Monitoring, Other Applications 3) By End User: Hospitals, Diagnostic Centers, Research Institutes, Other End Users Subsegments: 1) By Clinical Laboratory Improvement Amendments (CLIA): CLIA Waived Tests, Non-CLIA Tests 2) By Enzyme-Linked Immunosorbent Assay (ELISA): Sandwich ELISA Kits, Competitive ELISA Kits 3) By Fluorescence Immunoassay (FIA): Point-Of-Care FIA, Laboratory-Based FIA 4) By Other Types: Chemiluminescent Immunoassay (CLIA), Radioimmunoassay (RIA)What Is The Driver Of The Prostate Specific Antigen (PSA) Test Market?
The increasing prevalence of prostate cancer is expected to propel the growth of the prostate-specific antigen (PSA) test market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. The prostate-specific antigen (PSA) test is commonly used as a screening tool for prostate cancer in men. It measures the level of PSA in the bloodstream, which will help with early detection and risk assessment. For instance, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO), a US-based professional oncology organization, in the US, an estimated 288,300 men were diagnosed with prostate cancer, and approximately 34,700 people died in 2023. Therefore, the rise in the prevalence of prostate cancer is driving the growth of the prostate-specific antigen (PSA) test market.Key Players In The Global Prostate Specific Antigen (PSA) Test Market
Major companies operating in the prostate specific antigen (psa) test market are Siemens AG, F Hoffmann La Roche AG, Abbott Laboratories, Becton Dickinson And Company, PerkinElmer Inc, Beckman Coulter Inc, Bio Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, DiaSorin SpA, OPKO Health Inc, R And D Systems Inc, Meso Scale Diagnostics LLC, Tosoh America Inc, Fujirebio Europe NV, Boditech Med Inc, DRG International Inc, Enzo Life Sciences Inc, RayBiotech Inc, Novus Biologicals LLC, Creative Diagnostics Inc, Elabscience, LifeSpan BioSciences Inc, Accuquik Inc
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Prostate Specific Antigen (PSA) Test Market Trends and Insights
Major companies operating in the prostate-specific antigen (PSA) test market are focusing on product development and launches such as home testing kits for prostate-specific antigen (PSA) to sustain their position in the market. Home testing kits refer to self-administered diagnostic tools that allow individuals to collect samples, perform tests, and obtain results without the need for a visit to a healthcare facility. For instance, in September 2023, Randox, an Ireland-based health and toxicology company, unveiled an at-home testing kit for prostate-specific antigen (PSA). The PSA home test is designed to measure the levels of PSA in the blood, providing an indication of abnormalities within the prostate. PSA is a protein produced by prostate gland cells, and elevated levels can signal various conditions, including an enlarged prostate, prostatitis, or a urinary tract infection, in addition to the potential presence of prostate cancer.What Are Latest Mergers And Acquisitions In The Prostate Specific Antigen (PSA) Test Market?
In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, AstraZeneca PLC aims to enhance advanced radioconjugate technology for more targeted cancer treatments. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage oncology company that provides prostate-specific antigen (PSA) tests.
Regional Outlook
North America was the largest region in the prostate specific antigen (PSA) test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Prostate Specific Antigen (PSA) Test Market?
The prostate-specific antigen (PSA) test market includes revenues earned by entities by providing services such as prostate cancer detection, monitoring, PSA screening, prostatitis evaluation, complex PSA tests, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Prostate Specific Antigen (PSA) Test Market Report 2026?
The prostate specific antigen (psa) test market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate specific antigen (psa) test industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Prostate Specific Antigen (PSA) Test Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $5.19 billion |
| Revenue Forecast In 2030 | $8.17 billion |
| Growth Rate | CAGR of 12% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Siemens AG, F Hoffmann La Roche AG, Abbott Laboratories, Becton Dickinson And Company, PerkinElmer Inc, Beckman Coulter Inc, Bio Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, DiaSorin SpA, OPKO Health Inc, R And D Systems Inc, Meso Scale Diagnostics LLC, Tosoh America Inc, Fujirebio Europe NV, Boditech Med Inc, DRG International Inc, Enzo Life Sciences Inc, RayBiotech Inc, Novus Biologicals LLC, Creative Diagnostics Inc, Elabscience, LifeSpan BioSciences Inc, Accuquik Inc |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |